TIGIT Inhibitors Market Growth Accelerates With Expanding Immuno-Oncology Pipeline

Despite this progress, developers continue to face challenges related to selectivity, pharmacokinetics, pharmacodynamics, resistance, half-life, tumor penetration, and optimal combination strategies. Advances in computational modeling, structure-activity relationship studies, and rational drug design may support further development.

Leading TIGIT Inhibitors Shape Competitive Landscape

The competitive landscape includes several companies advancing potential TIGIT-targeted therapies. Key participants include Arcus Biosciences, Gilead Sciences, AstraZeneca, Compugen, Coherus Biosciences, Daiichi Sankyo, and other organizations involved in immuno-oncology research.

Domvanalimab, developed by Arcus Biosciences and Gilead Sciences, is a humanized IgG1 monoclonal antibody targeting TIGIT. Its mechanism is designed to prevent TIGIT from interacting with CD112 and CD155, potentially supporting CD226 signaling in NK cells and CD8+ T cells. Clinical development has included NSCLC and upper gastrointestinal malignancies.

Rilvegostomig, associated with AstraZeneca, Compugen, and Daiichi Sankyo, is a bispecific antibody designed to target both PD-1 and TIGIT. By simultaneously addressing these immune checkpoint pathways, the therapy is being investigated for its ability to enhance T-cell and NK-cell activity. Its clinical development includes NSCLC, head and neck squamous cell carcinoma, biliary tract cancer, and other solid tumors.

Additional candidates such as Casdozokitug (CHS-388) from Coherus Biosciences and COM902 from Compugen further contribute to pipeline diversity.

Strategic Collaborations Influence TIGIT Inhibitors Market Progress

Strategic collaborations are also supporting the development and commercialization potential of TIGIT-targeted therapies. Partnerships can provide access to development expertise, manufacturing capabilities, regulatory resources, and financial support while helping companies advance complex immuno-oncology programs.

Recent developments have highlighted continued commercial activity surrounding leading candidates. In December 2025, Compugen and AstraZeneca amended their 2018 exclusive license agreement concerning rilvegostomig, allowing Compugen to monetize part of its future royalties while supporting its broader pipeline. In October 2025, Arcus Biosciences reported overall survival results from Arm A1 of the Phase II EDGE-Gastric study evaluating domvanalimab with zimberelimab and chemotherapy in advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma.

In September 2025, Genentech presented Phase III results for tiragolumab combined with atezolizumab and bevacizumab as a first-line treatment approach in previously untreated locally advanced or metastatic hepatocellular carcinoma at ESMO 2025.

TIGIT Inhibitors Market Outlook Through 2034

Although clinical development has encountered inconsistent outcomes across some TIGIT programs, continued investigation of next-generation candidates and combination strategies remains an important feature of the market. Potential regulatory milestones for leading therapies could influence commercial opportunities and stimulate additional research across the target class.